Three papers go after blinding, the word "plasticity", and the main outcomes scale.
A JAMA Psychiatry viewpoint proposes UMBRAA — unidentifiable multidrug blinding with reduced, authorized awareness — to attack the masking problem head-on. Carhart-Harris and colleagues argue that popular neuroplasticity biomarkers often index canalization, the opposite of plasticity proper. And the Persisting Effects Questionnaire, used for decades, turns out not to support its assumed factor structure: it collapses to positive and negative, now with a validated short form.